Oppenheimer Upgrades GW Pharma (GWPH) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GW Pharma (GWPH) PT Raised to $227 at Stifel
May 7, 2019 8:37 AM EDTStifel analyst Paul Matteis raised the price target on GW Pharma (NASDAQ: GWPH) to $227.00 (from $191.00) while maintaining a Buy rating after spending time with management post 1Q print. The company reaffirmed views that the Epidiolex launch to date, considering all of the... More
GW Pharma (GWPH) PT Raised to $200 at Cowen
May 7, 2019 6:43 AM EDTCowen analyst Phil Nadeau raised the price target on GW Pharma (NASDAQ: GWPH) to $200.00 (from $175.00) while maintaining a Outperform rating following results.
The analyst commented, "GW reported $33.5MM in Epidiolex revenue during its first full quarter on the market, well ahead of consensus... More
GW Pharma (GWPH) PT Raised to $229 at Cantor Fitzgerald
May 7, 2019 6:42 AM EDTCantor Fitzgerald analyst Elemer Piros raised the price target on GW Pharma (NASDAQ: GWPH) to $229.00 (from $196.00) while maintaining a Overweight rating following Q1 results.
Piros commented, "The company reported the first full quarter of EPIDIOLEX revenues of $33.5 million. Additionally, GWPH reported positive... More
